Treatment of bacterial infections with cyclic antimicrobial peptides

• US 9,181,303 B2
• Filed: 06/20/2014
• Issued: 11/10/2015
• Est. Priority Date: 12/22/2005
• Status: Expired due to Fees

• Current Assignee: NovaBiotics Ltd.
• Original Assignee: NovaBiotics Ltd.
• Inventors: O'Neil, Deborah
• Primary Examiner(s): STOICA, ELLY GERALD
• Application Number:
  US14/311,093
• Publication Number:
  US 20140303071A1
• Time in Patent Office: 508 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/4723 Cationic antimicrobial peptides, e.g. defensins
• CPC Class Codes: C07K 7/64 Cyclic peptides containing only normal peptide links
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections.

Claims

1. A method of treating a bacterial infection in a subject, comprising administering to the subject a therapeutically effective amount of a composition of comprising a cyclic peptide and a pharmaceutically acceptable carrier, excipient or diluent, wherein the cyclic peptide comprises from 5 to 13 contiguous arginine residues and the bacterial infection is selected from the group consisting of:

Propionibacterium spp.; and

Clostridia spp.

2. The method of claim 1, wherein the arginine residues are D-amino acids.

3. The method of claim 1, wherein the arginine residues are L-amino acids.

9. The method of claim 1, wherein the bacterial infection is selected from the group consisting of Clostridium difficile;

and Propionibacterium acnes.

10. The method of claim 1, wherein the composition is administered topically.

4. A method of treating a bacterial infection in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising a cyclic peptide and a pharmaceutically acceptable carrier, excipient or diluent, wherein the cyclic peptide comprises 7 contiguous arginine residues and the bacterial infection is selected from the group consisting of:

Propionibacterium spp.; and

Clostridia spp.

5. The method of claim 4, wherein the bacterial infection is selected from the group consisting of:

Clostridium difficile; and

Propionibacterium acnes.

6. The method of claim 4, wherein the arginine residues are D-amino acids.

7. The method of claim 4, wherein the arginine residues are L-amino acids.

8. The method of claim 4, wherein the composition is administered topically.